Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Immunotherapy is the treatment of disease by inducing, enhancing or suppressing an immune response. Activation immunotherapies induce or amplify an immune response and are used in vaccines and as cancer immunotherapies. Suppression immunotherapies reduce or suppress an immune response and are used to prevent graft rejection and treat autoimmunity and allergy.
An oral inulin allergen gel restores the microbiota of allergic mice and suppresses undesired immune responses to achieve allergen-specific oral tolerance, effectively overcoming food allergy.
This Review discusses strategies for the design of cell–drug conjugates, the techniques for their preparation, and their translational applications, particularly for the treatment of cancers and autoimmune diseases.
In this phase 3 trial, first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma with anti-PD-1 finotonlimab plus cisplatin plus 5-fluorouracil (C5F) prolonged overall survival compared with placebo plus C5F.
RNA-sequencing data from NK-like CD57+ and PD-1+ CD8+ exhausted-like T cell populations linked to beneficial immunotherapy response in autoimmune patients suggest shared clonal relationships with each other and with common precursor populations.
The phase 3 NADINA trial showed impressive responses to neoadjuvant nivolumab plus ipilimumab relative to adjuvant nivolumab (the current best practice), revealing a new standard of care for patients with stage III melanoma.
An adoptive cellular therapy based on γδ T cells, which were engineered to secrete a tumour-targeting opsonin as well as an IL-15 superagonist, controlled tumour growth in a mouse model of patient-derived osteosarcoma.
Lyophilized lymph nodes are a natural scaffold to deliver chimeric antigen receptor (CAR) T cells to tumour resection sites, where they serve as a natural T cell-supporting niche and enhance CAR T cell efficacy in reducing recurrence in preclinical tumour resection models.